Apelin / ELABELA
Cardiovascular peptide system with significant heart-failure and longevity research interest.
Investigational compounds — read carefully
This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.
Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.
At a glance
Two endogenous peptide ligands for the APJ G-protein-coupled receptor, with substantial cardioprotective and metabolic biology. Heart-failure-with-preserved-ejection-fraction is the leading clinical interest area.
- Class
- APJ receptor agonists (peptides and engineered analogs)
- Sponsor
- Multiple academic / industry programs
- Stage
- Preclinical; Phase 1 in some programs
- Lead use case
- Heart failure (HFpEF), cardioprotection, metabolic disease
What it is
Apelin and ELABELA are endogenous peptide ligands for the APJ (apelin) receptor, a G-protein-coupled receptor expressed throughout the cardiovascular system, kidneys, and brain. Both have substantial preclinical evidence as cardioprotective signals; ELABELA was identified more recently (2013) and has distinct embryonic and developmental roles.
Current research status
Engineered apelin and ELABELA analogs are in preclinical and early Phase 1 development for heart failure and related cardiovascular indications. The native peptides have very short half-lives, so the central pharmaceutical challenge has been engineering for clinically relevant duration.
Mechanistic rationale
APJ activation produces inotropic effects on cardiac muscle, vasodilation, fluid-balance regulation, and cardioprotection during ischemia-reperfusion stress. The receptor is also implicated in metabolic regulation through effects on insulin sensitivity and adipose-tissue function. The pleiotropic profile is part of why the system has attracted interest across multiple therapeutic areas.
Available evidence
Cardiovascular preclinical — Apelin and ELABELA produce inotropic and vasodilatory effects in animal models, with cardioprotective effects in ischemia-reperfusion and heart-failure models.[1]
Human first-in-human studies — Native apelin infusion produces measurable hemodynamic effects (increased cardiac output, modest vasodilation) in healthy volunteers and in heart-failure patients.[2]
Engineered analogs — Several long-acting apelin analogs are in early-stage development.
Why it's interesting
Heart failure with preserved ejection fraction (HFpEF) is one of the largest unmet-need areas in cardiovascular medicine. Most cardiovascular pharmacology has focused on heart failure with reduced ejection fraction, and HFpEF has been notoriously difficult to treat. Apelin-pathway agonism produces effects that could be specifically relevant to the HFpEF pathophysiology — improving diastolic function, reducing fibrosis, and modulating fluid balance. If engineered apelin analogs translate into clinical efficacy, the molecule could become a meaningful HFpEF therapy.
Limitations & risks
The peptide engineering challenge — converting a sub-minute-half-life native peptide into a clinically dosable therapeutic — has been substantial. Several earlier programs in the apelin space have not advanced past Phase 1. Whether the current generation of engineered analogs can break this pattern is the open question.
Community discussion notes
Less discussed in biohacker and fitness communities than incretin or longevity peptides; the cardiovascular focus has kept the conversation more in clinical cardiology and academic discourse. Some longevity-community interest given the role of apelin signaling in vascular aging.
The takeaway
Apelin and ELABELA are a credible therapeutic pathway for cardiovascular and HFpEF indications. The translation distance from rich preclinical biology to clinical reality has been significant. The next 2-3 years of Phase 1 / Phase 2 readouts on engineered analogs will substantially shape whether the system becomes a clinical therapeutic option.
References
- Read C, et al. Cardiovascular protection by apelin and ELABELA: insights into the apelin pathway. Br J Pharmacol. 2019;176(20):3902-3916. https://pubmed.ncbi.nlm.nih.gov/?term=apelin+ELABELA
- Japp AG, et al. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation. 2010;121(16):1818-1827. https://pubmed.ncbi.nlm.nih.gov/20385929/